A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Dasatinib (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Feb 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 31 Mar 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.